CATABASIS PHARMACEUTICALS INC 4
4 · CATABASIS PHARMACEUTICALS INC · Filed Jun 30, 2015
Insider Transaction Report
Form 4
Modi Rick
Chief Business Officer
Transactions
- Conversion
Common Stock
2015-06-30+4,094→ 4,094 total - Conversion
Series B Preferred Stock
2015-06-30−52,614→ 0 total→ Common Stock (4,094 underlying)
Footnotes (1)
- [F1]The Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.